enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder De Solidarite Des Travai Fonds Sells 4,575 Shares of Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder De Solidarite Des Travai Fonds sold 4,575 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $15.01, for a total transaction of $68,670.75. Following the transaction, the insider now owns 3,084,107 shares in the company, valued at approximately $46,292,446.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

De Solidarite Des Travai Fonds also recently made the following trade(s):

• On Monday, April 22nd, De Solidarite Des Travai Fonds sold 47,854 shares of enGene stock. The stock was sold at an average price of $15.00, for a total value of $717,810.00.

enGene Stock Performance

NASDAQ ENGN opened at $14.80 on Tuesday. enGene Holdings Inc. has a 1 year low of $6.69 and a 1 year high of $43.00. The business’s 50-day moving average is $16.11.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Wells Fargo & Company started coverage on enGene in a report on Monday. They issued an “overweight” rating and a $30.00 price objective for the company. SVB Leerink assumed coverage on shares of enGene in a research report on Tuesday, February 20th. They set an “outperform” rating and a $31.00 price objective for the company. Leerink Partnrs reiterated an “outperform” rating on shares of enGene in a report on Tuesday, February 20th. UBS Group initiated coverage on shares of enGene in a report on Thursday, March 28th. They set a “buy” rating and a $37.00 target price for the company. Finally, Guggenheim assumed coverage on enGene in a report on Monday, April 15th. They issued a “buy” rating and a $34.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $34.40.

Institutional Investors Weigh In On enGene

Large investors have recently made changes to their positions in the company. Vivo Capital LLC acquired a new position in enGene in the 4th quarter worth approximately $6,264,000. Omega Fund Management LLC purchased a new stake in shares of enGene in the fourth quarter valued at $10,441,000. BVF Inc. IL acquired a new stake in shares of enGene in the fourth quarter worth $20,777,000. Finally, Fcpm Iii Services B.V. purchased a new position in shares of enGene during the fourth quarter valued at $80,097,000. Institutional investors and hedge funds own 64.16% of the company’s stock.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.